Early use of statins in acute coronary syndromes

被引:18
作者
Joshua M. Spin
Randall H. Vagelos
机构
[1] Stanford University Medical Center, Flak CVRB-279, Stanford
关键词
Statin; Acute Coronary Syndrome; Simvastatin; Pravastatin; Statin Therapy;
D O I
10.1007/s11883-003-0068-0
中图分类号
学科分类号
摘要
This review examines the use of statin medications early in the clinical course of acute coronary syndrome (ACS). Available data demonstrate that there are clear clinical benefits to this practice. Numerous previous studies have documented the primary and secondary benefits of statins in the prevention of coronary events. Recent trials show that when statins are used during hospital admissions for ACS, patients experience decreased recurrent myocardial infarction, lower death rates, and fewer repeat hospitalizations for ischemia or revascularization. Several studies suggest that the positive effects of statins on plaque stabilization, inflammation, thrombosis, and endothelial function may be independent of lipid levels. There is also an emerging view that beneficial lipid-lowering with statins in high-risk patients has no lower limit. This information suggests that all patients admitted for ACS should be treated with statins, regardless of cholesterol levels. Copyright © 2003 by Current Science Inc.
引用
收藏
页码:44 / 51
页数:7
相关论文
共 50 条
  • [31] The previous use of digoxin does not worsen early outcome of acute coronary syndromes: an analysis of the ARIAM Registry
    Juan Carlos Garcia-Rubira
    Manuel Calvo-Taracido
    Francisca Francisco-Aparicio
    Manuel Almendro-Delia
    Alejandro Recio-Mayoral
    Antonio Reina Toral
    Oscar Aramburu-Bodas
    Pastora Gallego García de Vinuesa
    José Maria Cruz Fernández
    Angel Garcia Alcántara
    Rafael Hidalgo-Urbano
    Internal and Emergency Medicine, 2014, 9 : 759 - 765
  • [32] The previous use of digoxin does not worsen early outcome of acute coronary syndromes: an analysis of the ARIAM Registry
    Carlos Garcia-Rubira, Juan
    Calvo-Taracido, Manuel
    Francisco-Aparicio, Francisca
    Almendro-Delia, Manuel
    Recio-Mayoral, Alejandro
    Reina Toral, Antonio
    Aramburu-Bodas, Oscar
    Gallego Garcia de Vinuesa, Pastora
    Cruz Fernandez, Jose Maria
    Garcia Alcantara, Angel
    Hidalgo-Urbano, Rafael
    INTERNAL AND EMERGENCY MEDICINE, 2014, 9 (07) : 759 - 765
  • [33] Through the Decades: β-Blocker Use and Outcomes in Acute Coronary Syndromes
    Kukin, Alina
    Noel, Zachary R.
    Watson, Kristin
    CARDIOLOGY IN REVIEW, 2018, 26 (03) : 157 - 166
  • [34] TicagrelorA Review of its Use in the Management of Acute Coronary Syndromes
    Emma D. Deeks
    Drugs, 2011, 71 : 909 - 933
  • [35] Effect of frailty on initiation of statins following incident acute coronary syndromes in patients aged >75 years
    Lopez, Derrick
    Nedkoff, Lee
    Briffa, Tom
    Preen, David B.
    Etherton-Beer, Christopher
    Flicker, Leon
    Sanfilippo, Frank M.
    MATURITAS, 2021, 153 : 13 - 18
  • [36] In-hospital Course of Early Invasive Strategy in Acute Coronary Syndromes
    Bassiri, H. A.
    Firoozi, A.
    Abdi, S.
    Sanati, H. R.
    Maadani, M.
    Shakerian, F.
    Salehi, N.
    Noohi, F.
    Alian, M. A.
    Amirpour, A.
    IRANIAN HEART JOURNAL, 2010, 11 (01): : 6 - 9
  • [37] The additive value of copeptin for early diagnosis and prognosis of acute coronary syndromes
    Ahmed, Tarek A. N.
    Johny, John S.
    Abdel-Malek, Mohamed Y.
    Fouad, Doaa A.
    AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2021, 50 : 413 - 421
  • [38] BivalirudinIn Patients with Acute Coronary Syndromes Planned for Urgent or Early Intervention
    Emma D. Deeks
    Monique P. Curran
    Drugs, 2008, 68 : 2345 - 2356
  • [39] Early Diagnosis Of Acute Coronary Syndromes With Automatic ST/T Classifier
    Terzi, Merve Begum
    Arikan, Orhan
    Abaci, Adnan
    Candemir, Mustafa
    Dedoglu, Mehmet
    2014 18TH NATIONAL BIOMEDICAL ENGINEERING MEETING (BIYOMUT), 2014,
  • [40] EptifibatideA pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes
    Greg L. Plosker
    Tim Ibbotson
    PharmacoEconomics, 2003, 21 : 885 - 912